This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.
Novartis gained 177Lu-PSMA-617 as part of its $2.1bn acquisition of Endocyte, which had a focus on radiopharmaceutical drugs for cancer, in October 2018. ... At the time, Novartis said radiopharma was a “key growth driver” for its business and that
The year saw it spend $8.7bn on acquiring gene therapy company AveXis and radiotherapy specialists Endocyte for $2.8bn.
Endocyte adding .
$8.7bn, and cancer specialist Endocyte for $2.1bn.
Heading up Endocyte’s pipeline is. 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). ... Novartis said radiopharma is a “key growth driver” for its business and that
If vintafolide is dropped, Endocyte will have to refocus its efforts on EC1456, a cancer drug for folate receptor-positive cancers in phase I testing. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the tumour through a tumour‐targeted ligand.
and eastern Europe - and US biotech Endocyte.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Prior to Ipsen, he held a number of leadership roles, including executive vice president and president of oncology at Baxalta, and chief commercial officer of Endocyte.
He also previously served at Novartis and Lilly. Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma ... In addition, Endocyte says it has three new drug
The appointments come at a crucial time for Endocyte as it prepares for the approval and launch of cancer drugs vintafolide (in partnership with Merck &Co) and etarfolatide. ... The two additions follow the hire in July 2012 of Endocyte's first chief
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...